How is retrospective independent review influenced by investigator-introduced informative censoring: A quantitative approach

Statistics in Medicine

Volumn 30, Issue 29, 2011, Pages 3373-3386

  Fleischer, Frank ^a   Gaschler Markefski, Birgit ^a   Bluhmki, Erich ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Independent review; Informative censoring; Oncology; Progression free survival; Survival analysis; Time to progression

Indexed keywords

ARTICLE; CANCER RESEARCH; CANCER SURVIVAL; DISCORDANCE RATE; HAZARD RATIO; HUMAN; INFORMATION PROCESSING; INFORMATIVE CENSORSHIP; PROBABILITY; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; QUANTITATIVE MODEL; RETROSPECTIVE INDEPENDENT REVIEW; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL MODEL; SYSTEMATIC ERROR;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; HUMANS; NEOPLASMS; RESEARCH DESIGN; RESEARCH PERSONNEL;

EID: 81955164248     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4379     Document Type: Article

References (23)

1. Flemming TR, Rothmann MD, Lu HL. Issues in Using Progression-Free Survival When Evaluating Oncology Products. Journal of Clinical Oncology 2009; 27:2874-2880. DOI: 10.1200/JCO.2008.20.4107.
2. Broglio KR, Berry DA. Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival. Journal of the National Cancer Institute 2009; 101:1642-1649. DOI: 10.1093/jnci/djp369.
3. Tuma R. Progression-Free Survival Remains Debatable Endpoint in Cancer Trials. Journal of the National Cancer Institute 2009; 101:1439-1441.
4. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P. Progression-free survival is a surrogate for survival in advanced colorectal cancer. Journal of Clinical Oncology 2007; 25:5218-5224. DOI: 10.1200/JCO.2007.11.8836.
5. Louvet C, de Gramont A, Tournigand A, Artru P, Maindrault-Goebel F, Krulik M. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 2001; 91:2033-2038. DOI: 10.1002/1097-0142(20010601)91:11<2033::AID-CNCR1229>3.0.CO;2-J.
6. Tang AP, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. Journal of Clinical Oncology 2007; 25:4562-4568. DOI: 10.1200/JCO.2006.08.1935.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guidelines (version 1.1). European Journal of Cancer 2009; 45:228-247.
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 2000; 92:205-216. DOI: 10.1093/jnci/92.3.205.
9. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2007.
10. Dodd LE, Korn LE, Freidlin B, Jaffe C, Rubinstein LV, Dancey J, Mooney MM. Blinded Independent Independent review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense? Journal of Clinical Oncology 2008; 26:3791-3796. DOI: 10.1200/JCO.2008.16.1711.
11. Chakravarty AG. PFS as an endpoint - Regulatory Considerations. Presentation at the DIA Progression-free survival oncology workshop, Washington, 2009.
12. Amit O, Mannino F. An audit methodology for independent review of PFS. Presentation at the DIA Progression-free survival oncology workshop, Washington, 2009.
13. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley: New York, 2002.
14. Carroll KJ. Analysis of progression-free survival in oncology trials: some common statistical issues. Pharmaceutical Statistics 2007; 6:99-113. DOI: 10.1002/pst.251.
15. Kay R, Wu J, Wittes J. On assessing the presence of evaluation-time bias in progression-free survival in randomized trials. Pharamceutical Statistics 2011; 10:213-217. DOI: 10.1002/pst.443.
16. Xu J, Kabfleisch J, Tai B. Statistical analysis of illness death processes and semi-competing risks data. Biometrics 2010; 66:716-725. DOI: 10.1111/j.1541-0420.2009.01340.x.
17. Dejardin D, Lesaffre E, Verbeke G. Joint Modelling of Progression Free Survival and Death in Advanced Cancer Clinical trials. Statistics in Medicine 2010; 29:1724-1734. DOI: 10.1002/sim.3918.
18. Fleischer F, Gaschler-Markefski B, Bluhmki E. A statistical model for the dependence between progression-free survival and overall survival. Statistics in Medicine 2009; 28:2669-2686. DOI: 10.1002/sim.3637.
19. DiRenzio AG. Nonparametric comparison of two survival-time distributions in the presence of dependent censoring. Biometrics 2003; 59:497-504. DOI: 10.1111/1541-0420.00059.
20. Rothmann MD, Koti K, Lee KY, Lu HL, Shen YL. Missing Data in Biologic Oncology Products. Journal of Biopharmaceutical Statistics 2009; 19:1074-1084. DOI: 10.1080/10543400903242993.
21. Yu RX, Holmgren E. Endpoints for agents that slow tumor growth. Contemporary Clinical Trials 2007; 28:18-24. DOI: 10.1016/j.cct.2006.05.011.
22. Zhao Q, Sun J. Generalized log-rank test for mixed interval-censored failure time data. Statistics in Medicine 2004; 23:1621-1629. DOI: 10.1002/sim.1746.
23. Goggins WB, Finkelstein DM, Schoenfeld DA, Zaslavsky AM. A Markov chain EM algorithm for analyzing interval-censored data under the Cox proportional hazards model. Biometrics 1998; 54:1498-1507.